Ashley Moody Highlights Lack of Pharmaceutical Transparency and Foreign Supply Chain Risks

Foreign Dependence and Drug Supply Chains

• ⚠️ Ashley Moody highlights that over 50% of drug manufacturers supplying the U.S. market are from overseas.
• 💡 It's noted that China and India combined produce 85% of active pharmaceutical ingredients (APIs).
• 🌍 This dependence is an unintended consequence of globalization over the last 20 years, with the COVID-19 pandemic exposing the fragility of these supply chains.

FDA Violations and Manufacturing Risks

• 🚨 A significant concern is that drug and API manufacturers in China and India receive the most FDA warning letters for violations.
• 🚩 These violations can include issues like carcinogens in medicines, falsifying data, and non-sterile manufacturing.
• 📊 Currently, one in every four prescriptions in the U.S. comes from a facility with an FDA violation.

Lack of Transparency and Consumer Awareness

• ❓ There is a severe lack of transparency in the pharmaceutical industry, unlike other supply chains where product origin and quality can be compared.
• 📉 Experts and government officials initially underestimated the risk of shortages and over-reliance on foreign nations.
• 📢 Implementing country of origin labeling on medications could significantly increase awareness among consumers, doctors, and pharmacists about these risks.

Potential Solutions and National Security

• 💰 Bringing manufacturing back to the United States is proposed as a solution, with estimates suggesting it could cost less than a penny per dose.
• 🔒 The hearing also touched upon the national security implications of failures within the pharmaceutical supply chain.
• 📈 Efforts are underway to close the perception gap regarding these risks through publications and continued awareness campaigns.